Author(s)

Eduardo Mansilla^1*, Ricardo Rangel Martínez², Gustavo Horacio Marín³, Idiberto Zotarelli Filho⁴, Elsa Rivas⁵, Jaime Rivas⁶, Katherine Athayde Teixeira de Carvalho⁷, Mohammad Reza Dayer⁸, Alí Samadikuchaksaraei⁹

¹Internal Medicine, School of Medical Sciences, UNLP, La Plata, Argentina.
²ExomePharma, Ciudad de México DF, México.
³Pharmacology, School of Medical Sciences, UNLP, La Plata, Argentina.
⁴Faceres Medical School, Sao José do Rio Preto, Sao Paulo, Brazil.
⁵Intensive Care Units-Hospital de la Amistad Perú Corea II, Santa Rosa and Salvador University Hospital, Piura, Perú.
⁶Intensive Care Unit, Hospital de la Amistad Perú Corea II, Santa Rosa, Piura, Perú.
⁷Pequeno Príncipe Faculty & Pelé Pequeno Príncipe Institute, Curitiba, Paraná, Brazil.
⁸Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran.
⁹Department of Tissue Engineering & Regenerative Medicine, Iran University of Medical Sciences, Tehran, Iran.

SARS-CoV-2 is a novel RNA coronavirus responsible of a deadly pandemic: the clinical illness COVID-19. With only one authorized drug for emergency use in critically ill patients: Remdesivir, there is not any other approved drug or vaccine yet with proven potential to overcome this infection. We exposed here many scientific evidences to support our novel idea that a macrolide, basically Clarithromycin, could be effective as a single agent for treatment and prophylaxis of COVID-19. Clarithromycin could change the history of this pandemic. It could reduce the costs of treatment and the potential adverse effects when combining more than one drug such as with Hydroxychloroquine. Clarithromycin treatment and prophylaxis as a single agent could be much more simple, safe and cheaper as giving Chloroquine or Hydroxychloroquine alone or in combination with Azithromycin as well as other therapeutic options.

COVID-19, Macrolides, Clarithromycin, Single Agent, Therapy, Prophylaxis

Mansilla, E. , Martínez, R. , Marín, G. , Filho, I. , Rivas, E. , Rivas, J. , Carvalho, K. , Dayer, M. and Samadikuchaksaraei, A. (2020) Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent. Pharmacology & Pharmacy, 11, 85-104. doi: 10.4236/pp.2020.116009.